373 related articles for article (PubMed ID: 35488021)
1. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
Cesaro S; Ljungman P; Mikulska M; Hirsch HH; von Lilienfeld-Toal M; Cordonnier C; Meylan S; Mehra V; Styczynski J; Marchesi F; Besson C; Baldanti F; Masculano RC; Beutel G; Einsele H; Azoulay E; Maertens J; de la Camara R; ; Pagano L
Leukemia; 2022 Jun; 36(6):1467-1480. PubMed ID: 35488021
[TBL] [Abstract][Full Text] [Related]
2. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).
Cesaro S; Mikulska M; Hirsch HH; Styczynski J; Meylan S; Cordonnier C; Navarro D; von Lilienfeld-Toal M; Mehra V; Marchesi F; Besson C; Masculano RC; Beutel G; Einsele H; Maertens J; de la Camara R; ; Ljungman P; Pagano L
Leukemia; 2023 Sep; 37(9):1933-1938. PubMed ID: 37460673
[No Abstract] [Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia.
Bergeron A; Mikulska M; De Greef J; Bondeelle L; Franquet T; Herrmann JL; Lange C; Spriet I; Akova M; Donnelly JP; Maertens J; Maschmeyer G; Rovira M; Goletti D; de la Camara R;
Lancet Infect Dis; 2022 Dec; 22(12):e359-e369. PubMed ID: 35636446
[TBL] [Abstract][Full Text] [Related]
5. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Guo W; Zheng Y; Feng S
Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
[TBL] [Abstract][Full Text] [Related]
6. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
Mikulska M; Testi D; Russo C; Balletto E; Sepulcri C; Bussini L; Dentone C; Magne F; Policarpo S; Campoli C; Miselli F; Cilli A; Ghiggi C; Aquino S; Di Grazia C; Giannella M; Giacobbe DR; Vena A; Raiola AM; Bonifazi F; Zinzani P; Cavo M; Lemoli R; Angelucci E; Viale P; Bassetti M; Bartoletti M
Br J Haematol; 2023 May; 201(4):628-639. PubMed ID: 36806152
[TBL] [Abstract][Full Text] [Related]
7. Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Campbell A; Teh B; Mulligan S; Ross DM; Weinkove R; Gilroy N; Gangatharan S; Prince HM; Szer J; Trotman J; Lane S; Dickinson M; Quach H; Enjeti AK; Ku M; Gregory G; Hapgood G; Ho PJ; Cochrane T; Cheah C; Greenwood M; Latimer M; Berkahn L; Wight J; Armytage T; Diamond P; Tam CS; Hamad N
Intern Med J; 2024 Feb; 54(2):328-336. PubMed ID: 38146232
[TBL] [Abstract][Full Text] [Related]
8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
[TBL] [Abstract][Full Text] [Related]
13. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).
Mallet V; van Bömmel F; Doerig C; Pischke S; Hermine O; Locasciulli A; Cordonnier C; Berg T; Moradpour D; Wedemeyer H; Ljungman P;
Lancet Infect Dis; 2016 May; 16(5):606-617. PubMed ID: 27599653
[TBL] [Abstract][Full Text] [Related]
14. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
Sanchez-Pina JM; Rodríguez Rodriguez M; Castro Quismondo N; Gil Manso R; Colmenares R; Gil Alos D; Paciello ML; Zafra D; Garcia-Sanchez C; Villegas C; Cuellar C; Carreño-Tarragona G; Zamanillo I; Poza M; Iñiguez R; Gutierrez X; Alonso R; Rodríguez A; Folgueira MD; Delgado R; Ferrari JM; Lizasoain M; Aguado JM; Ayala R; Martinez-Lopez J; Calbacho M
Eur J Haematol; 2020 Nov; 105(5):597-607. PubMed ID: 32710500
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Goldman JD; Robinson PC; Uldrick TS; Ljungman P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117116
[TBL] [Abstract][Full Text] [Related]
16. Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.
Shaw B; Shortt J; Low M; Rogers B; Kaplan Z; Fedele P; Gregory G; Vilcassim S; Gilbertson M; Grigoriadis G; Opat S
Intern Med J; 2022 Dec; 52(12):2172-2175. PubMed ID: 36436197
[TBL] [Abstract][Full Text] [Related]
17. Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study.
Lund LC; Rahbek MT; Brown P; Obel N; Hallas J; Frederiksen H
Eur J Haematol; 2023 Dec; 111(6):946-950. PubMed ID: 37740535
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy.
Kampouri E; Hill JA; Dioverti V
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14144. PubMed ID: 37767643
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir is effective in patients with haematological malignancies.
Bołkun Ł; Pula B; Kołkowska-Leśniak A; Morawska M; Cichocka E; Charlinski G; Garus B; Giebel S; Piszcz J; Drozd-Sokolowska J; Kwiatkowski J; Biernat M; Hus I; Lech-Maranda E; Długosz-Danecka M; Giannopoulos K; Wróbel T
Int J Cancer; 2023 Sep; 153(6):1251-1256. PubMed ID: 36691818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
